Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer: a Pilot Study
Combination Chemotherapy of Heptaplatin, Paclitaxel and 5-Fluorouracil in Patients with Advanced Gastric Cancer:a Pilot Study
2
조회
0
다운로드
0
인용
0
참고문헌
초록
Abstract
PURPOSE: To evaluate the efficacy and toxicity of heptaplatin, paclitaxel, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. MATERIALS AND METHODS: Between July 2002 and September 2003, nineteen patients were enrolled in this study. Paclitaxel 135 mg/m2 iv on day 1, heptaplatin 400 mg/m2 iv on day 2 and 5-fluorouracil 800 mg/m2 on day 2~4 were administered and the regimen was repeated every 3 weeks. RESULTS: The median age of the patients was 60 years (range: 32~74) and the most common sites of metastasis were liver and lymph nodes. In the 16 evaluated patients, the overall response rate was 43.8%, but this was without any complete response. The median time to disease progression was 3.93 months (range: 0.26~8.1) and the median response duration for the 7 responding patients was 3.83 months (range: 1.48~6.07). The median overall survival for 19 patients was 7.01 months (range: 0.26~17.44). A median of 3 cycles (range: 1~7) and a total of 65 cycles were administered and evaluated for toxicity. The most common hematologic toxicities were NCI grade I/II anemia (47.7%), neutropenia (9.2%) and thrombocytopenia (6.2%). The most common non-hematologic toxicities more than grade II were nausea/vomiting (30.8%/9.2%). One elderly patient with ECOG 2 had a life- threatening complication of pneumonia. CONCLUSION: The combination of heptaplatin, paclitaxel, and 5-fluorouracil showed significant activity and favorable toxicity profiles in patients with advanced gastric cancer. However, one elderly patient who had poor performance experienced a life-threatening toxicity/complication. Our results suggest that the efficacy of this combination chemotherapy can be maximized when administered to the patients with good performance status. Further studies with large numbers of patients and long-term follow-up study will be needed. (Cancer Res Treat. 2004;36:182-186)
참고문헌 (21)
- "Annual report of theCentral Cancer Registry in Korea-2000:based on registereddata from 131 hospitals", 34(2), pp.77~83 (2002)
- "Randomizedcomparison of fluorouracil,epidoxorubicin and methotrexateplus supportive care with supportive care alone in patients withnon-resectable gastric cancer", 71, pp.587~591 (1995)
- "Modified therapy with 5-fluorouracil,doxorubicinand methotrexate in advanced gastric cancer", 72, pp.37~41 (1993)
- "Initial of delayed chemotherapy with best supportive care inadvanced gastric cancer", 5, pp.189~190 (1994)
- "Palliative chemotherapyversus supportive care in patients with metastatic gastriccancer: a randomized trial" (1995), Second International Conference onBiology, Prevention and Treatment of GI Malignancy, Koln
- "FAMTXversus etoposide,doxorubicin and cisplatin:a random assignmenttrial in gastric cancer", 10, pp.541~548 (1992)
- "Final results of a randomizedPhase III trial of sequential high-dose methotrexate leucovorin and fluorouracilversus infusional fluorouracil and cisplatin in advancedgastric cancer cooperative group", 18, pp.2648~2657 (2000)
- "Randomized trial comparingepirubicin, cisplatin and fluorouracil versus fluorouracil,doxorubicin, and methotrexate in advanced esophagogastriccancer", 15, pp.261~267 (1997)
- "A phase III randomized studyof 5-fluorouracil and cisplatin versus 5-fluorouracil alone in thetreatment of advanced gastric cancer", 71, pp.3813~3818 (1993)
- "A phase III study of UFT+MMC versus 55-FU+CDPP versus 5-FU alone in patientswith advanced gastric cancer;JCOG study 9205", 18, pp.272~ (1999)
- platinum(II), , 1998, 109~116
- platinum(II) as determinedby ex vivo pharmacodynamics, , 1995, 1~6
- "Phase II clinical trial ofSKI-2053R,a new platinum analog,in the treatment of patientswith advanced gastric adenocarcinoma", 86, pp.1109~1115 (1999)
- "SKI 2053R and 5-fluorouracil(5-FU) in advanced gastric adenocarcinoma; phase II clinicaltrial", 19, pp.323~ (2000)
- "Phase II trial of the combination ofpaclitaxel and 5-fluorouracil in the treatment of advancedgastric cancer:a novel,safe,and effective regimen", 22, pp.580~586 (1999)
- "Paclitaxel,5-fluorouracil,andcisplatin combination chemotherapy in the treatment ofadvanced gastric carcinoma", 85, pp.295~301 (1999)
- "A phase II study of paclitaxel FA andcisplatin in patients with advanced gastric cancer", 83, pp.458~462 (2000)
- "Arandomized controlled trial of fluorouracil plus leucovorin,irinotecan,and oxaliplatin combinations in patients withpreviously untreated metastatic colorectal cancer", 22, pp.23~30 (2004)
- "Pilot study ofheptoplatin, UFT-E, and leucovorin in advanced gastriccarcinoma", 35(2), pp.117~122 (2003)
- "A phase II study of capecitabine in patients with advanced-metastatic gastriccarcinoma", 20, pp.142~ (2001)
- "Phase IIstudy of S-1,a novel oral derivative of 5-fluorouracil inadvanced gastric cancer", 58, pp.191~197 (2000)